BioInformant

Your Global Leader in Stem Cell Market Research

MENUMENU
  • Blog
  • Stem Cells
    • iPS Cells
    • MSCs
    • HSCs
    • Adipose SCs
    • Neural Stem Cells
  • Cell Therapy
    • COVID-19
    • CAR-T
    • Cord Blood
  • Exosomes
  • Interviews
  • News
    • Press Releases
    • Job Posts
  • Shop
    • Products
    • Submit PR
    • Advertise
  • About
    • Testimonials
    • Story
    • Guarantee
    • Contact
  • Home
  • Blog
    • Stem Cells
      • HSCs
      • iPS Cells
      • MSCs
      • Neural Stem Cells
      • Adipose SCs
    • Exosomes
    • Cell Therapy
      • CAR-T
    • Cord Blood
    • Stem Cell News
    • Interviews
  • COVID-19
  • Shop
  • Submit PR
  • Company
    • Advertise
    • Testimonials
    • Story
    • Job Posts
    • Guarantee
    • Privacy Policy
    • Contact
Home » exosomes

List of Exosome Companies: Tiny Packages, Enormous Potential

February 24, 2021 By Cade Hildreth (CEO) 2 Comments

Feature | Exosome Companies | Exosome Companies | Tiny Exosomes, Enormous Potential

Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits. [Read more…]

Filed Under: Exosomes Tagged With: exosomes

Exosomes: Company Spotlights from “A” to “Z”

December 7, 2020 By Cade Hildreth (CEO)

Exosomes

Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.

In recent years, exosomes have gained attention as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering the cells to patients.

With at least 13,703 scientific articles published about exosomes and 169 clinical trials underway, these small vesicles have intriguing potential to be used within a range of therapeutic applications. [Read more…]

Filed Under: Exosomes Tagged With: exosomes

EVerZom raises €1.1M to industrialize its exosome biomanufacturing platform

November 30, 2020 By Cade Hildreth (CEO)

EVerZom Exosome Biomanufacturing-platform
EVerZom’s ambition is to transform regenerative medicine and the field of biotherapies thanks to these «super» biological nanoparticles, the exosomes.

Paris, November 30, 2020 — EVerZom, a biopharmaceutical company specialized in the bioproduction of exosomes, announced today that it has raised €1.1 million in funding from institutional and private investors to develop its exosome bioproduction platform. This funding will speed up the platform development and scale-up, with the objective to allow routine clinical grade production by 2022. [Read more…]

Filed Under: Exosomes, Press Releases Tagged With: exosomes

Organicell Partners with Regenerative Care Network to Study Potential Therapeutic Benefits of Zofin™ for Patients with Heart Failure

October 20, 2020 By Cade Hildreth (CEO)

Organicell Zofin heart failure

MIAMI, Oct. 20, 2020 — Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced that it has recently entered into an agreement with Regenerative Care Network (“RCN”). Organicell and RCN plan to collaborate on clinical research projects investigating use of Organicell’s lead therapeutic, Zofin™, as a novel therapeutic for heart failure with preserved ejection fraction, known as HFpEF. [Read more…]

Filed Under: Coronavirus (COVID-19), Press Releases, Stem Cell News Tagged With: exosomes, Organicell

FDA Approves Two Emergency INDs for COVID-19 Outpatient Therapy

August 6, 2020 By Cade Hildreth (CEO)

Organicell emergency INDs COVID-19

First Reported eIND Issued for Outpatient COVID-19 Therapy

Miami, FL (August 6, 2020) ­— Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) approved two outpatient Emergency Investigational New Drug Applications (eINDs) for treating mild to moderate respiratory distress due to COVID-19. [Read more…]

Filed Under: Coronavirus (COVID-19), Exosomes, Press Releases, Stem Cell News Tagged With: exosomes

  • 1
  • 2
  • 3
  • …
  • 9
  • Next Page »

Let’s Get Social

  • Facebook
  • Twitter
  • Instagram
  • Pinterest
  • LinkedIn

Nanocellect

Marathon Products

Menu
  • Blog
  • Stem Cell News
    • Press Releases
  • Stem Cells
    • HSCs
    • iPS Cells
    • MSCs
    • Neural Stem Cells
    • Adipose SCs
  • Exosomes
  • Cell Therapy
    • CAR-T
  • Cord Blood
  • Interviews

Cart

Top Rated Products

  • US Cord Blood and Cord Tissue Storage Rates Rates of U.S. Cord Blood and Cord Tissue Storage - Historical and Projected
    Rated 0 out of 5
    $197
  • Job Posting on BioInformant Job Posting on BioInformant.com - Your Perfect Hire Is In Our Audience
    Rated 0 out of 5
    $297
  • BioInformant Audience Reach BioInformant's Audience with Your Press Announcement
    Rated 0 out of 5
    $397 $297
My Tweets

BioInformant's World-Class Clients

  • Submit Press Release
  • Advertise
  • Privacy and Terms

Copyright © 2021 · BIOINFORMANT, Your Global Leader in Stem Cell Market Research

| Email: [email protected] | Phone: 703-859-7617 |

800 Corporate Drive, Suite 301, Stafford, VA 22554, United States

Disclaimer: All statements made on this website are NOT expressed as medical claims or advice. They are not intended to diagnose, treat, cure or prevent any disease or condition. If you have a health condition or concern, consult your physician or health care provider.